December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pluristyx, Inc.

News headline image
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx and Solesis Launch First-of-its-Kind PluriForm™-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx and Accelerated Biosciences Announce Availability of Clinical-Grade Immune-Privileged Human Trophoblast Stem Cells (hTSCs)
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells
From Pluristyx, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.